



REVASCULARIZATION DEVICE

Penumbra System[®]

Excellent Revascularization and Good Clinical Outcomes

Analysis of Penumbra System[®] and 3D[®]



3D Trial Results²

| | Penumbra System | Penumbra System [®] + 3D [™] | P-Value | |
|-----------------------|-----------------|---|---------|--|
| n | 86 | 87 | | |
| TICI 2b/3 | 74% | 84% | 0.14 | |
| mRS ≤ 2 at 90 days | 48% | 42 % | 0.4295 | |
| SICH | 3.5% | 3.4% | 1.0 | |

Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387 (10029):1723-1731.
 Nogueira RG, on behalf of the Penumbra 3D Investigators. The 3D Trial: A randomized study comparing the Penumbra Stent Retriever with aspiration vs. aspiration alone in acute ischemic stroke. Paper presented at: 9th Annual Meeting of the Society of Vascular and Interventional Neurology, November 16-19, 2016, Brooklyn, NY, USA.

3D REVASCULAR FATION DEVICE

Designed for Use with Aspiration

- Unique architecture minimizes vessel wall contact¹ to facilitate atraumatic procedure
 - Four intraluminal chambers secure and maximize clot extraction into ACE[™] Reperfusion Catheter
 - Optimized radial force provides effective clot integration and smooth device withdrawal into ACE Reperfusion Catheter
 - Provides up to five retrieval passes into ACE Reperfusion Catheter

3D[™] is specifically designed to be used with Penumbra System[®] Aspiration



Deliver with Velocity[®] Microcatheter or 3MAX[®] Reperfusion Catheter Aspirate with ACE[®]60, ACE64, or ACE68



Unique architecture minimizes vessel wall contact¹ Four intraluminal chambers secure and maximize clot extraction

Penumbra System[®] and 3D[™] Cases





Images courtesy of Dr. Don Frei Swedish Medical Center, CO, USA



eximal larker Reperfusion Catheter Four Distal Markersone on each intraluminal chamber

Four distal markers along length of 3D[®] provide accurate device placement





Images courtesy of Dr. Don Heck Forsyth Medical Center, NC, USA



Ordering Information

Penumbra System®

| Catalog Number | Description | Proximal OD | Distal OD | Proximal ID | Distal ID | Working Length | |
|--------------------------------|--|---|--|---|---|--|--|
| Aspiration Kits | | | | | | | |
| 5MAXACE068KIT | ACE™68 Beperfusion Catheter+Penumbra Hi-Flow Tubing | 6 0 E (080'') | 60 F | 068" | 068" | 132 cm | |
| 5MAXACE064KIT | ACE64 Reperfusion Catheter+Penumbra Hi-Flow Tubing | 6.0 F (.080") | 5.75 F | .000 | 064" | 132 cm | |
| 5MAXACE132KIT | ACE60 Reperfusion Catheter+Penumbra Hi-Flow Tubing | 6.0 F (.080") | 54 F | 068" | 060" | 132 cm | |
| PSC054KIT | 5MAX [™] Benerfusion Catheter+Penumbra Hi-Flow Tubing | 6.0 F (.080") | 50 F | .000 | 054" | 132 cm | |
| 4MAXCKIT | 4MAX [™] Reperfusion Catheter+Penumbra Hi-Flow Tubing | 6.0 F (.080") | 4.3 F | .064" | .041" | 139 cm | |
| 3MAXCKIT | 3MAX [™] Reperfusion Catheter+Penumbra Hi-Flow Tubing | 4.7 F (.062") | 3.8 F | .043" | .035" | 153 cm | |
| Revascularization Device | | Diameter | Device Length | Working Length | | | |
| PSR3D – <i>New!</i> | 3D Revascularization Device | 4.5 mm | 26 mm | 20 mm | | | |
| Reperfusion Catheters | | Indication For Us | se | | | | |
| 5MAXACE068 | ACE68 Reperfusion Catheter | Penumbra Syste | Penumbra System Reperfusion Catheters and Separators | | | | |
| 5MAXACE064 | ACE64 Reperfusion Catheter | patients with acut | e ischemic stroke secondar | y to intracranial large vessel o | cclusive disease (within | the internal carotid, middle | |
| 5MAXACE132 | ACE60 Reperfusion Catheter | cerebrai – M1 and intravenous tissue | cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. | | | | |
| PSC054 | 5MAX Reperfusion Catheter | Penumbra 3D Re | Penumbra 3D Revascularization Device | | | | |
| 4MAXC | 4MAX Reperfusion Catheter | patients with acut | patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle | | | | |
| 3MAXC | 3MAX Reperfusion Catheter | cerebral – M1 and M2 segments) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasmino- gen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. | | | | ntravenous tissue plasmino- | |
| | | As part of the Pen | ation Tubing umbra System, the Penumb | ra Sterile Aspiration Tubing is | indicated to connect th | e Penumbra Reperfusion | |
| Separator [®] Devices | 51437.0 | Catheters to the P Penumbra Aspir | enumbra Aspiration Pump. ation Pump | | | | |
| PSF054 | 5MAX Separator | The Penumbra As | piration Pump is indicated a | s a vacuum source for Penum | bra Aspiration Systems | | |
| PSF041 | 4MAX Separator | There are no know | s vn contraindications. | | | | |
| 3MAXS | 3MAX Separator | • The Penumbra 9 | Warnings • The Penumbra System should only be used by physicians who have received appropriate training in interventional neuro-en- | | | | |
| | | dovascular tech | niques and treatment of acu | te ischemic stroke. | | | |
| Delivery Microcatheter | | Do not advance, cause using fluc | , retract or use any compone proscopy. If the cause canno | ent of the Penumbra System a t be determined, withdraw the | gainst resistance witho e device or system as a | ut caretul assessment of the unit. Unrestrained torquing or | |
| VEL160STR | Velocity [™] Microcatheter | forced insertion | of the catheter, revascularia | ation device, or Separator aga | ainst resistance may res | sult in damage to the device | |
| | | Do not use the F | enumbra System with a pu | mp other than the Penumbra A | Aspiration Pump. | | |
| Aspiration Accessories | | The Penumbra 3 arterial injury. | 3D Revascularization Device | has not been evaluated in pat | tients with angiographic | evidence of pre-existing | |
| PMX110 | Pump MAX ^{***} | Precautions | | | | | |
| PAPS2 | MAX Canister | The device is information catheter coating | ended for single use only. D I lubrication, which mav res | o not resterilize or reuse. Rest ult in high friction and the inab | erilization and/or Reuse ility to access the targe | t neuro vasculature location. | |
| | | Do not use kinke | ed or damaged devices. Do | not use open or damaged pac | kages. Return all damad | ed devices and packaging to | |

Neuron[™] MAX 6 F 088 Lumen Long Sheath

| Catalog Number | Description | Tip Shape | Working Length |
|--------------------|---|---------------|-------------------|
| (Crosscut Valve, I | RHV, and Dilator Included) | | |
| PNML6F088904 | 6 F 088 Neuron MAX Long Sheath, 90/4 Straight | Ţ | 90 cm |
| PNML6F088904M | 6 F 088 Neuron MAX Long Sheath, 90/4 MP | \mathcal{D} | 90 cm |

6 F Select[™] Catheters

²opular configuration

| Catalog Number | Description | Tip Shape | Working Length |
|----------------|--------------------------------------|--------------|-------------------|
| PNS6F105H1 | 6 F Select [™] Catheter, H1 | 5 | 105 cm |
| PNS6F105BER | 6 F Select Catheter, BER | าโ | 105 cm |
| PNS6F125H1 | 6 F Select Catheter, H1 | J | 125 cm |
| PNS6F125SIM | 6 F Select Catheter, SIM | ∎] | 125 cm |
| PNS6F125SIMV | 6 F Select Catheter, SIMV | Ś | 125 cm |
| PNS6F125BER | 6 F Select Catheter, BER | 1 | 125 cm |





the manufacturer/distributor.

damage the device.

Potential Adverse Events

Penumbra Europe GmbH Am Borsigturm 44 13507 Berlin Germany T +49 30 2005 676-0 F +49 30 2005 676-10 erder@oenumbraine.do order@penumbrainc.de

The manufacturer/instructor. Use prior to the "Use By" date. • Use the Penumbra System in conjunction with fluoroscopic visualization. • Maintain a constant infusion of appropriate flush solution. • When performing aspiration, ensure that the Penumbra Aspiration Tubing valve is open for only the minimum time needed to remove thrombus. Excessive aspiration or failure to close the Penumbra Aspiration Tubing valve when aspiration is complete is not recommended. • The Penumbra Separator is not intended for use as a neurovascular unidewire. If repositioning of the Penumbra Reperfusion

The Penumbra Separator is not intended for use as a neurovascular guidewire. If repositioning of the Penumbra Reperfusion Catheter is necessary during the revascularization procedure, such repositioning should be performed over an appropriate neurovascular guidewire using standard microcatheter and guidewire techniques.
 Do not use automated high-pressure contrast injection equipment with the Penumbra Reperfusion Catheter because it may

Administration of anticoagulants and antiplatelets should be suspended until 24 hours post-treatment. Medical management and acute post stroke care should follow the ASA guidelines. Any neurological deterioration should be evaluated by urgent CT scan and other evaluations as indicated according to investigator/hospital best practice. As in all surgical interventions, monitoring of intra-procedural blood loss is recommended so that appropriate management

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media, acute occlusion, air embolism, arteriovenous fistula, death, device malfunction, distal embolization, emboli, false aneurysm for-mation, hematoma or hemorrhage at access site, inability to completely remove thrombus, infection, intracranial hemorrhage, ischemia, kidney damage from contrast media, neurological deficits including stroke, vessel spasm, thrombosis, dissection, or

Ischemia, kidney damage from contrast media, neurological dencits including stroke, vessel spasm, thromoosis, dissection, i perforation.
Adams et al., Guidelines for the Early Management of Adults with Ischemic Stroke: A Guideline from the AHA/ASA Stroke Council Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Artherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists, Stroke May 2007; 38: 1655-1711.

Product availability varies by country. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Proto to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Images used with permission. Consents on file at Penumbra, Inc. Please contact your local Penumbra representative for more information.

may be instituted. • Limit the usage of Reperfusion Catheters to arteries larger than the catheter's outer diameter.

bra Neuro Australia Pty Ltd Suite 3, Level 5, 1 Oxford Stree Darlinghurst NSW 2010 Australia T +61-1300 817 025 F +61-1300 817 026 order.anz@penumbrainc.com

www.penumbrainc.com

Copyright ©2017 Penumbra, Inc. All rights reserved. The Penumbra P logo, Penumbra System, 3D Revascularization Device, 3D, ACE, MAX, Separator, Velocity, Neuron, and Select are registered trademarks or trademarks of Penumbra, Inc. in the USA and other countries. 11823 Rev. A 04/17 USA